目的 探討尤瑞克林聯(lián)合依達拉奉對急性腦梗死患者血清同型半胱氨酸（Hcy）、血清超敏C-反應蛋白（hs-CRP）和D-二聚體水平的影響。方法 將河南大學附屬南陽南石醫(yī)院自2015年1月-2017年10月收治的急性腦梗死患者160例作為研究對象，隨機分為兩組，觀察組86例給予尤瑞克林聯(lián)合依達拉奉進行治療，對照組74例單純給予依達拉奉進行治療，兩組均治療2周。對比觀察兩組患者的治療效果和血清Hcy、hs-CRP和D-二聚體水平變化情況。結果 觀察組患者治療后臨床總有效率為91.86%，顯著高于對照組的79.73%，差異有統(tǒng)計學意義（P<0.05）。治療后兩組患者Hcy、hs-CRP和D-二聚體水平及NIHSS評分均顯著降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且觀察組以上指標顯著低于對照組，差異有統(tǒng)計學意義（P<0.05）。結論 對急性腦梗死患者在常規(guī)治療的基礎上使用尤瑞克林聯(lián)合依達拉奉治療，可有效改善患者臨床效果、神經功能恢復，降低血清炎癥介質的水平，達到改善預后的目的，可推廣使用。

Objective To investigate the effect of uricorlin combined with edaravone on the levels of serum Hcy, hs-CRP and D-dimer in patients with acute cerebral infarction. Methods 160 patients with acute cerebral infarction treated in our hospital from January 2015 to October 2017 were randomly divided into two groups. The study group was treated with urelixin and edaravone in 86 cases. In the control group, 74 cases were treated with edaravone alone. The treatment effects and changes of serum inflammatory factors in the two groups were observed and compared.Results The total effective rate was 91.86% in the study group and 79.73% in the control group. The difference between the two groups was statistically significant (P<0.05). The scores of hs-CRP, D-dimer, and NIHSS scores were significantly lower, and the reduction level in the study group was significantly better than that in the control group. The difference between the groups was statistically significant (P<0.05).Conclusion s The use of urelixin in combination with edaravone in the treatment of acute cerebral infarction patients can effectively improve the clinical efficacy and neurological function recovery, reduce the level of serum inflammatory mediators, can improve the prognosis and can be promoted.

國家自然青年基金項目（81500323）